Image Place holder

Nikhil I. Khushalani, MD

Vice Chair, Department of Cutaneous Oncology

Specialty: Medical Oncology
Program: Cutaneous Oncology

Call 1-888-MOFFITT
(1-888-663-3488)

or call 1-888-MOFFITT
(1-888-663-3488)

Overview

Dr. Khushalani is the Vice Chair for the Department of Cutaneous Oncology at Moffitt Cancer Center. Dr. Khushalani’s clinical interest is the development of novel therapeutics for people diagnosed with melanoma and other skin cancers. He is greatly interested in the treatment of uveal melanoma, and melanoma that has metastasized to the brain. Dr. Khushalani is interested in research on angiogenesis in melanoma and the translation of findings into clinical therapeutics. He is studying the economic impact of new melanoma drugs on healthcare (pharmacoeconomics) with an aim to devise strategies to reduce cost. Dr. Khushalani earned his MD from Topiwala National Medical College, University of Bombay, in Maharashtra, India. He completed an Internal Medicine Residency at the State University of New York (SUNY) at Buffalo, where he also served as Chief Resident. He completed a Medical Oncology Fellowship at Roswell Park Cancer Institute in 2002. Dr. Khushalani was Assistant Professor of Oncology at Roswell Park Cancer Institute and, prior to joining the Moffitt team, was Associate Professor of Medicine at SUNY, Buffalo, where he was the Section Chief of Soft Tissue and Melanoma Medicine, and Director of the IL-2 Program.       

Education & Training

Board Certification:

  • Medical Oncology

Fellowship:

  • Roswell Park Cancer Institute - Medical Oncology

Residency:

  • KEM Hospital and Seth GS Medical Collage - Internal Medicine
  • State University of New York - Internal Medicine

Medical School:

  • T.N. Medical College University of Bombay - MBBS
Participating Trials

CLINICAL TRIAL 17937
A Phase 1/2 Dose Escalation and Cohort Expansion Study of the Safety and Tolerability of Urelumab Administered in Combination with Nivolumab in Advanced /Metastatic Solid Tumors and B Cell Non-Hodgkins Lymphoma
Condition: Cutaneous
Intervention: BMS-936558 (Nivolumab); Nivolumab; Not Applicable; Urelumab
Open

CLINICAL TRIAL 18686
An Observational Pilot Study to Compare the Compliance with and Health Related Quality of Life during Therapy with Standard High-Dose Interferon Alfa (Intron® A, HDI) versus Pegylated Alfa-Interferon 2b (Sylatron, PEG IFN) in Patients with Surgically Resected Melanoma
Condition: Cutaneous
Intervention: PEG-Intron (Peginterferon Alfa 2B); interferon alfa
Open

CLINICAL TRIAL 18874
A Phase 1b/2 Study to Assess the Safety and Efficacy of HBI-8000 in Combination with Nivolumab in Patients with Advanced Solid Tumors Including Melanoma, Renal Cell Carcinoma (RCC) and Non-Small Cell Lung Cancer (NSCLC)
Condition: Cutaneous
Intervention: BMS-936558 (Nivolumab); HBI-8000 (chidamide); Nivolumab
Open

CLINICAL TRIAL 18933
Phase II Study of Pembrolizumab and Ipilimumab Following Initial Anti-PD1/L1 Antibody
Condition: Cutaneous
Intervention: Ipilimumab; Pembrolizumab (Keytruda); Yervoy (Ipilimumab)
Open

CLINICAL TRIAL 18309
A Phase 2, Multicenter, Single-arm Study to Assess the Safety, Feasibility, and Efficacy of Cell Transfer Therapy Using Autologous Tumor Infiltrating Lymphocytes (LN-144) Followed by IL-2 for Treatment of Metastatic Melanoma
Condition: Cutaneous
Intervention: Aldesleukin (Interleukin-2); IL-2 (Interleukin-2); Interleukin-2; Proleukin (Interleukin-2); TIL
Open

CLINICAL TRIAL 17974
An Open-Label, Multicenter, Dose-Escalation, Phase 1b/2 Study of the Safety, Efficacy, Pharmacodynamics, and Pharmacokinetics of RTA 408 in Combination With Ipilimumab or Nivolumab in the Treatment of Patients With Unresectable or Metastatic Melanoma
Condition: Cutaneous
Intervention: BMS-936558 (Nivolumab); Ipilimumab; Nivolumab; RTA 408; Yervoy (Ipilimumab)
Open

CLINICAL TRIAL 18916
A Phase 2 Study of Ibrutinib (PCI-32765) in Refractory Distant Metastatic Cutaneous Melanoma: Correlation of Biomarkers with Response and Resistance
Condition: Cutaneous
Intervention: 748645 (Ibrutinib); Ibrutinib (Imbruvica); PCI-32765 (Ibrutinib)
Open

CLINICAL TRIAL 18906
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors
Condition: Multiple
Intervention: BMS-936558 (Nivolumab); Nivolumab; TSR-022; TSR-042
Open

CLINICAL TRIAL 18826
A Phase 1 Study of ALKS 4230 in Subjects with Advanced Solid Tumors
Condition: Genitourinary
Intervention: ALKS 4230
Open

CLINICAL TRIAL 18527
Non-Comparative, Open-Label, Multiple Cohort, Phase 1/2 Study of Nivolumab Monotherpay and Nivolumab Combination Therapy in Subjects with Virus-Positive and Virus-Negative Solid Tumors
Condition: Multiple
Intervention: BMS-936558 (Nivolumab); Ipilimumab; Nivolumab; Not Applicable; Yervoy (Ipilimumab)
Open

CLINICAL TRIAL 18527
Non-Comparative, Open-Label, Multiple Cohort, Phase 1/2 Study of Nivolumab Monotherpay and Nivolumab Combination Therapy in Subjects with Virus-Positive and Virus-Negative Solid Tumors
Condition: Multiple
Intervention: BMS-936558 (Nivolumab); Ipilimumab; Nivolumab; Not Applicable; Yervoy (Ipilimumab)
Open

CLINICAL TRIAL 18786
A Phase 2, Randomized, Multi-institutional Study of Nivolumab and Ipilimumab versus Nivolumab, Ipilimumab and Stereotactic Body Radiation Therapy for Metastatic Merkel Cell Carcinoma
Condition: Cutaneous
Intervention: BMS-936558 (Nivolumab); Ipilimumab; Nivolumab; Yervoy (Ipilimumab)
Open

CLINICAL TRIAL 18989
A Phase 1b/2 Study of PV-10 Intralesional Injection in Combination with Systemic Immune Checkpoint Inhibition for Treatment of Metastatic Melanoma
Condition: Cutaneous
Intervention: PV-10; Pembrolizumab (Keytruda)
Open

CLINICAL TRIAL 18975
A Phase 2 Study of REGN2810, a Fully Human Monoclonal Antibody to Programmed Death-1, in Patients with Advanced Basal Cell Carcinoma who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy
Condition: Cutaneous
Intervention: REGN2810
Open

If you believe you are eligible for one of these trials or studies, please call
1-888-MOFFITT (1-888-663-3488).

Publications

  • Sondak VK, Khushalani NI. Adjuvant and Neoadjuvant Therapy in High-Risk Stage III Cutaneous Melanoma. Int J Radiat Oncol Biol Phys. 2017 May;98(1):16-17. Pubmedid: 28586957.
  • Fountzilas C, Chhatrala R, Khushalani N, Tan W, LeVea C, Hutson A, Tucker C, Ma WW, Warren G, Boland P, Iyer R. A phase II trial of erlotinib monotherapy in advanced pancreatic cancer as a first- or second-line agent. Cancer Chemother Pharmacol. 2017 Jul. Pubmedid: 28702772.
  • Larkin J, Minor D, D'Angelo S, Neyns B, Smylie M, Miller WH, Gutzmer R, Linette G, Chmielowski B, Lao CD, Lorigan P, Grossmann K, Hassel JC, Sznol M, Daud A, Sosman J, Khushalani N, Schadendorf D, Hoeller C, Walker D, Kong G, Horak C, Weber J. Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial. J Clin Oncol. 2017 Jul. Pubmedid: 28671856.
  • Zimmer L, Apuri S, Eroglu Z, Kottschade LA, Forschner A, Gutzmer R, Schlaak M, Heinzerling L, Krackhardt AM, Loquai C, Markovic SN, Joseph RW, Markey K, Utikal JS, Weishaupt C, Goldinger SM, Sondak VK, Zager JS, Schadendorf D, Khushalani NI. Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma. Eur J Cancer. 2017 Apr;75:47-55. Pubmedid: 28214657.
  • Strom T, Torres-Roca JF, Parekh A, Naghavi AO, Caudell JJ, Oliver DE, Messina JL, Khushalani NI, Zager JS, Sarnaik A, Mulé JJ, Trotti AM, Eschrich SA, Sondak VK, Harrison LB. Regional Radiation Therapy Impacts Outcome for Node-Positive Cutaneous Melanoma. J Natl Compr Canc Ne. 2017 Apr;15(4):473-482. Pubmedid: 28404758.
  • Khushalani NI, Sondak VK. Are we there yet? Prolonged MAPK inhibition in BRAF(V600)-mutant melanoma. Lancet Oncol. 2016 Sep;17(9):1178-1179. Pubmedid: 27480104.
  • Pokuri VK, Tomaszewski GM, Ait-Oudhia S, Groman A, Khushalani NI, Lugade AA, Thanavala Y, Ashton EA, Grande C, Fetterly GJ, Iyer R. Efficacy, Safety, and Potential Biomarkers of Sunitinib and Transarterial Chemoembolization (TACE) Combination in Advanced Hepatocellular Carcinoma (HCC): Phase II Trial. Am J Clin Oncol. 2016 Mar. Pubmedid: 27014931.
  • Johnson DB, Sullivan RJ, Ott PA, Carlino MS, Khushalani NI, Ye F, Guminski A, Puzanov I, Lawrence DP, Buchbinder EI, Mudigonda T, Spencer K, Bender C, Lee J, Kaufman HL, Menzies AM, Hassel JC, Mehnert JM, Sosman JA, Long GV, Clark JI. Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders. JAMA Oncol. 2016 Feb;2(2):234-240. Pubmedid: 26633184.
  • Luu C, Khushalani NI, Zager JS. Intralesional and systemic immunotherapy for metastatic melanoma. Expert Opin Biol Ther. 2016 Dec;16(12):1491-1499. Pubmedid: 27602429.
  • Brohl AS, Khushalani NI, Eroglu Z, Markowitz J, Thapa R, Chen YA, Kudchadkar R, Weber JS. A phase IB study of ipilimumab with peginterferon alfa-2b in patients with unresectable melanoma. J Immunother Cancer. 2016 Dec;4:85. Pubmedid: 28031816. Pmcid: PMC5170897.
  • Ahmed KA, Abuodeh YA, Echevarria MI, Arrington JA, Stallworth DG, Hogue C, Naghavi AO, Kim S, Kim Y, Patel BG, Sarangkasiri S, Johnstone PA, Sahebjam S, Khushalani NI, Forsyth PA, Harrison LB, Yu M, Etame AB, Caudell JJ. Clinical outcomes of melanoma brain metastases treated with stereotactic radiosurgery and anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK inhibitors, BRAF inhibitor, or conventional chemotherapy. Ann Oncol. 2016 Dec;27(12):2288-2294. Pubmedid: 27637745.
  • Jarkowski A, Hare R, Loud P, Skitzki JJ, Kane JM, May KS, Zeitouni NC, Nestico J, Vona KL, Groman A, Khushalani NI. Systemic Therapy in Advanced Cutaneous Squamous Cell Carcinoma (CSCC): The Roswell Park Experience and a Review of the Literature. Am J Clin Oncol. 2016 Dec;39(6):545-548. Pubmedid: 24879468.
  • Wei L, Liu S, Conroy J, Wang J, Papanicolau-Sengos A, Glenn ST, Murakami M, Liu L, Hu Q, Conroy J, Miles KM, Nowak DE, Liu B, Qin M, Bshara W, Omilian AR, Head K, Bianchi M, Burgher B, Darlak C, Kane J, Merzianu M, Cheney R, Fabiano A, Salerno K, Talati C, Khushalani NI, Trump DL, Johnson CS, Morrison CD. Whole-genome sequencing of a malignant granular cell tumor with metabolic response to pazopanib. Cold Spring Harb Mol Case Stud. 2015 Oct;1(1):a000380. Pubmedid: 27148567. Pmcid: PMC4850888.
  • Oxenberg J, Khushalani NI, Salerno KE, Attwood K, Kane JM. Neoadjuvant chemotherapy for primary cutaneous/soft tissue angiosarcoma: Determining tumor behavior prior to surgical resection. J Surg Oncol. 2015 Jun;111(7):829-833. Pubmedid: 25772798.
  • McDermott DF, Cheng SC, Signoretti S, Margolin KA, Clark JI, Sosman JA, Dutcher JP, Logan TF, Curti BD, Ernstoff MS, Appleman L, Wong MK, Khushalani NI, Oleksowicz L, Vaishampayan UN, Mier JW, Panka DJ, Bhatt RS, Bailey AS, Leibovich BC, Kwon ED, Kabbinavar FF, Belldegrun AS, Figlin RA, Pantuck AJ, Regan MM, Atkins MB. The high-dose aldesleukin "select" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma. Clin Cancer Res. 2015 Feb;21(3):561-568. Pubmedid: 25424850. Pmcid: PMC4315731.
  • Weber JS, D'Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, Hoeller C, Khushalani NI, Miller WH, Lao CD, Linette GP, Thomas L, Lorigan P, Grossmann KF, Hassel JC, Maio M, Sznol M, Ascierto PA, Mohr P, Chmielowski B, Bryce A, Svane IM, Grob JJ, Krackhardt AM, Horak C, Lambert A, Yang AS, Larkin J. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015 Apr;16(4):375-384. Pubmedid: 25795410.
  • Saraceni MM, Khushalani NI, Jarkowski A. Immunotherapy in Melanoma: Recent Advances and Promising New Therapies. J Pharm Pract. 2015 Apr;28(2):193-203. Pubmedid: 24674910.
  • Jarkowski A, Khushalani NI. BRAF and beyond: Tailoring strategies for the individual melanoma patient. J Carcinog. 2014 Feb;13:1. Pubmedid: 24737949. Pmcid: PMC3986540.
  • Jarkowski A, Nestico JS, Vona KL, Khushalani NI. Dose rounding of ipilimumab in adult metastatic melanoma patients results in significant cost savings. J Oncol Pharm Pract. 2014 Feb;20(1):47-50. Pubmedid: 23512270.
  • Iyer R, Chhatrala R, Shefter T, Yang G, Malhotra U, Tan W, Levea C, Robins M, Khushalani N. Erlotinib and radiation therapy for elderly patients with esophageal cancer - clinical and correlative results from a prospective multicenter phase 2 trial. Oncology-Basel. 2013 Sep;85(1):53-58. Pubmedid: 23860007.
  • Coit DG, Andtbacka R, Anker CJ, Bichakjian CK, Carson WE, Daud A, Dilawari RA, Dimaio D, Guild V, Halpern AC, Hodi FS, Kelley MC, Khushalani NI, Kudchadkar RR, Lange JR, Lind A, Martini MC, Olszanski AJ, Pruitt SK, Ross MI, Swetter SM, Tanabe KK, Thompson JA, Trisal V, Urist MM. Melanoma. J Natl Compr Canc . 2012 Mar;10(3):366-400. Pubmedid: 22393197.
  • Damodaran S, Bellavia T, Sait SN, Wang ES, Wetzler M, Khushalani NI. Acute myeloid leukemia secondary to oxaliplatin treatment for esophageal cancer. Clin Colorectal Cancer. 2012 Jun;11(2):151-154. Pubmedid: 22133502.
  • Jarkowski A, Hare R, Francescutti V, Wilkinson N, Khushalani N. Case report of pneumatosis intestinalis secondary to sunitinib treatment for refractory gastrointestinal stromal tumor. Anticancer Res. 2011 Oct;31(10):3429-3432. Pubmedid: 21965757.
  • Yang GY, May KS, Iyer RV, Chandrasekhar R, Wilding GE, McCloskey SA, Khushalani NI, Yendamuri SS, Gibbs JF, Fakih M, Thomas CR. Renal atrophy secondary to chemoradiotherapy of abdominal malignancies. Int J Radiat Oncol Biol Phys. 2010 Oct;78(2):539-546. Pubmedid: 20133075.
  • Puthillath A, Mashtare T, Wilding G, Khushalani N, Steinbrenner L, Ross ME, Romano K, Wisniewski M, Fakih MG. A phase II study of first-line biweekly capecitabine and bevacizumab in elderly patients with metastatic colorectal cancer. Crit Rev Oncol Hematol. 2009 Sep;71(3):242-248. Pubmedid: 19081732.
  • Yang GY, McClosky SA, Khushalani NI. Principles of modern radiation techniques for esophageal and gastroesophageal junction cancers. Gastrointest Cancer Res. 2009 Mar;3(2 Suppl 1):S6-S10. Pubmedid: 19461922. Pmcid: PMC2684733.
  • Khushalani N. Cancer of the esophagus and stomach. Mayo Clin Proc. 2008 Jun;83(6):712-722. Pubmedid: 18533089.
  • Ramnath N, Yu J, Khushalani NI, Gottlieb RH, Schwarz JK, Iyer RV, Rustum YM, Creaven PJ. Scheduled administration of low dose irinotecan before gemcitabine in the second line therapy of non-small cell lung cancer: a phase II study. Anticancer Drugs. 2008 Aug;19(7):749-752. Pubmedid: 18594219.